(19)
(11) EP 4 565 585 A1

(12)

(43) Date of publication:
11.06.2025 Bulletin 2025/24

(21) Application number: 23761384.9

(22) Date of filing: 02.08.2023
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61K 31/437(2006.01)
A61P 35/00(2006.01)
C07D 487/04(2006.01)
A61K 31/4985(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 471/04; C07D 487/04; A61P 35/00
(86) International application number:
PCT/US2023/071535
(87) International publication number:
WO 2024/030968 (08.02.2024 Gazette 2024/06)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 03.08.2022 US 202263370307 P

(71) Applicant: Bristol-Myers Squibb Company
Princeton, NJ 08543 (US)

(72) Inventors:
  • QIAO, Jennifer X.
    Princeton, New Jersey 08543 (US)
  • WILLIAMS, David K.
    Princeton, New Jersey 08543 (US)
  • GILL, Patrice
    Princeton, New Jersey 08543 (US)
  • DHAR, T.G. Murali
    Princeton, New Jersey 08543 (US)
  • TOKARSKI, John S.
    Princeton, New Jersey 08543 (US)
  • GAVAI, Ashvinikumar V.
    Princeton, New Jersey 08543 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) COMPOUNDS FOR MODULATING RET PROTEIN